Pfizer gets positive top-line results from Phase III atopic dermatitis study
The company is developing abrocitinib, a JAK1 inhibitor, for the disease. Incyte is also developing a topical formulation of its JAK2 inhibitor for atopic dermatitis.
The company is developing abrocitinib, a JAK1 inhibitor, for the disease. Incyte is also developing a topical formulation of its JAK2 inhibitor for atopic dermatitis.